Novel tremelimumab-durvalumab regimen safe, effective in advanced liver cancer

A single 300 mg priming dose of tremelimumab in combination with durvalumab appeared safe and active among patients with advanced hepatocellular carcinoma, according to study results presented during the ASCO20 Virtual Scientific Program.The results suggest the regimen has a better benefit-risk profile than tremelimumab administered in 75 mg doses with durvalumab or monotherapy with either drug, researchers noted.“Immune checkpoint inhibition with anti-PD-L1 and anti-CTLA-4 antibodies drive antitumor activity and have demonstrated durable immune responses in subsets of patients withRead More

Share on facebook
Share on twitter
Share on linkedin